OCTOPLUS convenes EGM on 15 January 2013
Date: 13.12.2012
With reference to the joint press releases by OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO) and Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") dated 22 October 2012 and 16 November 2012, OctoPlus today announces that it calls an Extraordinary General Meeting of Shareholders pursuant to Article 2:108a of the Dutch Civil Code (Burgerlijk wetboek) and in connection with the intended public offer by an indirect wholly owned subsidiary of Dr. Reddy's for all the issued and outstanding shares in the capital of OctoPlus pursuant to Article 18, paragraph 1 of the Dutch Public Takeover Decree (Besluit openbare biedingen Wft) (the "Decree").
Extraordinary General Meeting of Shareholders to take place on 15 January 2013 in Leiden
An Extraordinary General Meeting of Shareholders of OctoPlus has been called to be held on 15 January 2013, 14.00 hours CET, at OctoPlus' headquarters in Leiden. The meeting documents are now available in the Corporate Information section of the website www.octoplus.nl.
This press release does not constitute or form part of an offer for ordinary shares in OctoPlus. It is an announcement that an Extraordinary General Meeting of Shareholders of OctoPlus has been called. The information in this press release is not intended to be complete and for further information explicit reference is made to the offer memorandum, which is expected to be published mid December 2012, after approval of the Dutch Authority for the Financial Markets (Stichting Autoriteit Financiële Markten). In addition, a position statement of the Executive Board and Supervisory Board of OctoPlus shall be made available in accordance with Article 18, paragraph 2 and annex G of the Decree.
For further information, please contact:
For further information about OctoPlus, please contact Investor Relations: telephone number +31 (71) 524 1064, or send an e-mail to Investor Relations at IR@octoplus.nl.
Author: OctoPlus
About OctoPlus
OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on our proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies.
OctoPlus also focuses on the development of long-acting, controlled release versions of known protein therapeutics, peptides and small molecules, including specialty generics. OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.
OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.
This is a press release by OctoPlus pursuant to provisions of Article 5:25i of the Dutch Act on the Financial Supervision (Wet op het financieel toezicht) and Article 4, paragraph 3 of the Decree, in connection with the intended public offer by an indirect wholly owned subsidiary of Dr. Reddy's for all the issued and outstanding shares in the capital of OctoPlus.
